Table 2:
Categorization of Events
| Alloimmune Events by ATG Induction | ||
|---|---|---|
| Non-ATG (N = 77) | ATG (N = 26) | |
| Alloimmune Event-n(%) | 18(23) | 4(15) |
| Non-ATG Alloimmune Events(N=18) | ATG Alloimmune Events(N=4) | |
| ACR 1A-n(%) | 1(5.5) | 0(0) |
| ACR 1B-n(%) | 1(5.5) | 1(25) |
| ACR 2A-n(%) | 1(5.5) | 0(0) |
| ACR 3-n(%) | 1(5.5) | 0(0) |
| Borderline-n(%) | 7(39) | 1(25) |
| Class I dnDSA-n(%) | 0(0) | 1(25) |
| Class II dnDSA-n(%) | 7(39) | 1(25) |
| Infection Events by ATG Type | ||
| Non-ATG (N = 77) | ATG (N = 26) | |
| Infection Event-n(%) | 53(69) | 13(50) |
| Non-ATG Infection Events (N=53) | ATG Infection Events (N=13) | |
| BKV-n(%) | 11(21) | 1(8) |
| CMV-n(%) | 6(11) | 1(8) |
| CMV/other viral infection-n(%) | 2(4) | 0(0) |
| EBV-n(%) | 18(34) | 7(53) |
| EBV/BKV-n(%) | 1(2) | 0 |
| EBV/other viral infection-n(%) | 0(0) | 1(8) |
| Other viral infection-n(%) | 15(28) | 3(23) |
In total there were N=66 infections or 64% of the total cohort. In total, there were 22 alloimmune endpoints (21% of the total cohort). Grading based on Banff 2011 criteria. Abbreviations: BKV-BK Virus; EBV-Epstein-Barr Virus; CMV-Cytomegalovirus